Aardvark Therapeutics, Inc. Material Event - What Happened

This report explains the latest news from Aardvark Therapeutics in plain English, so you can understand the situation without needing a finance degree.

1. What happened?

On May 14, 2026, the FDA placed a "full clinical hold" on Aardvark’s lead drug, ARD-101. This forces an immediate pause on all ongoing clinical trials. This affects the Phase 3 "HERO" trial and the "open-label extension" (OLE) study, where previous participants continue to receive the medication.

2. What is the company doing about it?

Aardvark is "unblinding" the data from these trials to address the FDA’s concerns.

• What does "unblinding" mean? Usually, researchers and patients do not know who is receiving the drug versus a placebo to keep results fair. By unblinding, the company can now see exactly who received the treatment and how they fared. This allows management to review the health outcomes of all 87 patients to see if the FDA’s concerns involve specific safety issues or broader problems.

3. Why does this matter?

This is a major hurdle. Aardvark is a "clinical-stage" company, meaning they do not yet sell any products for profit. Their entire value depends on the success and approval of ARD-101, which treats extreme hunger in patients with Prader-Willi Syndrome.

However, the company has a financial cushion. As of March 31, 2026, Aardvark held $91.2 million in cash. Management expects this to fund operations until mid-2027. This gives them time to review their data and talk to the FDA without the immediate pressure of running out of money.

4. Who is affected?

• Investors: Shareholders face high uncertainty. Because the company’s value relies almost entirely on ARD-101, this hold creates significant risk. Expect higher stock price swings until the company clarifies the data and the FDA’s requirements.
• Patients: The 68 patients in the HERO trial and 19 in the OLE study must stop their participation. They will now follow safety protocols required by the FDA.
• The Company: Management has shifted focus from running trials to fixing regulatory issues. Their main goal is to find the cause of the FDA's concern and create a plan to move forward.

5. What should investors know?

• Watch the "Unblinding" results: The next major update will be the company’s interpretation of the unblinded data. Look for clues on whether the safety concerns are minor or if they point to a fundamental problem with the drug.
• Cash is vital: The $91.2 million balance is key. Because they are funded through mid-2027, they do not need to issue more shares right now. This protects your current ownership percentage while they navigate this challenge.
• Patience is required: Regulatory processes are slow. The FDA must review any new data or plans before the hold can be lifted. Expect a period of limited updates while the company and the FDA communicate.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and should not be considered professional investment advice. Always do your own research before buying or selling stocks.